LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
Real Endpoints is an information and data/analytics company focused on providing reimbursement, pricing and market intelligence to stakeholders in the healthcare industry.
Among its products are unique tools that can be used by manufacturers to assess the value of marketed and pipeline drugs from a payer’s point of view, an insight that can enhance their efforts to obtain favorable reimbursement. Other products can be used to guide investment and strategy choices by showing which access challenges a new drug will face and how severe they’ll be.
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.